Skip to main content
Premium Trial:

Request an Annual Quote

Epoch Said Strong Q2 Sales, Lower R&D Helped Keep Net Loss Static

NEW YORK, July 30 - Epoch Biosciences today said strong second-quarter  product sales helped drive total revenue, while a slight decrease in R&D spending helped keep net loss unchanged.

 

For the three-month period ended June 30, Epoch said total revenue climbed to $2.5 million from $1.8 million on year ago. Product sales, which grew to $1.7 million from $1.1 million in the year-ago period, led the growth followed by a modest growth in licensing fees and royalties, the firm said.

 

R&D spending in the current second quarter, meanwhile, fell to $1.1 million from $1.2 million year over year, according to Epoch. Spending on sales and marketing, however, increased to $319,000 in the second quarter 2002 from $106,000 in the same period one year ago.

 

As a result, Epoch said second-quarter net loss was virtually unchanged year over year at $1.2 million, or $.05 per share.

 

The company said it had roughly $5 million in cash and cash equivalents as of June 30. It had about $8.4 during the same period one year ago.

 

Click here for more information.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.